Senti Biosciences Holdings, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.090
+0.020 (1.87%)
At close: Jun 26, 2026, 4:00 PM EDT
1.050
-0.040 (-3.67%)
After-hours: Jun 26, 2026, 7:46 PM EDT
SNTI Employees
Senti Biosciences Holdings had 39 employees as of December 31, 2025. The number of employees increased by 5 or 14.71% compared to the previous year.
Employees
39
Change (1Y)
5
Growth (1Y)
14.71%
Revenue / Employee
$974
Profits / Employee
-$1,321,718
Market Cap
33.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39 | 5 | 14.71% |
| Dec 31, 2024 | 34 | -14 | -29.17% |
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Daré Bioscience | 24 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
| Barinthus Biotherapeutics | 14 |
| Nutriband | 13 |
SNTI News
- 9 days ago - Senti Biosciences Holdings Registration statement: Registration filing - Filings
- 6 weeks ago - Senti Bio completes Type B RMAT meeting with FDA on SENTI-202 - TheFly
- 6 weeks ago - Senti Biosciences Holdings Earnings release: Q1 2026 - Filings
- 6 weeks ago - Senti Biosciences Holdings Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase - GlobeNewsWire
- 6 weeks ago - Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - GlobeNewsWire
- 2 months ago - Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - GlobeNewsWire
- 2 months ago - Senti Biosciences Holdings Slides: Corporate presentation - Filings